DeepSeek to Raise AI API Prices as Demand for New Models Surges 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
CHESTERBROOK, Pa., Feb. 28, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call on Wednesday, March 7, 2018 at 8:00 am EST to review financial results as of and for the quarter and year ended December 31, 2017 and to discuss recent corporate highlights.
To join the call, please dial-in at (855) 465-0180 (conference ID: 7843918).
To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 7843918). Following the conclusion of the call, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
SVP, scientific affairs and investor relations officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
